Ascletis Starts Phase III Trial of Oral GLP-1 Drug
Hong Kong, China, August 30, 2026 Ascletis Pharma Inc. announced that the first participant has been dosed in its...
metabolic disease
Advertisement
Hanmi Pharm Licenses Obesity Drug HM17321 to Genentech
SEOUL, South Korea, August 24, 2026 Hanmi Pharm announced an exclusive global licensing agreement with Genentech, a member of...
PTC Therapeutics Highlights Sephience PKU Data at SSIEM 2026
Warren, New Jersey, August 24, 2026 PTC Therapeutics, Inc. announced that new clinical and real-world evidence for Sephience™ (sepiapterin)...
Ultragenyx Wins FDA Approval for GENGLYCOS Gene Therapy
Novato, California, August 19, 2026 Ultragenyx Pharmaceutical Inc. has announced that the U.S. Food and Drug Administration (FDA) granted...
Amylyx Pharmaceuticals Reports Positive Phase 3 Results
CAMBRIDGE, Mass., August 18, 2026 Amylyx Pharmaceuticals, Inc. announced positive topline results from the Phase 3 LUCIDITY clinical trial...
Advertisements
Arrowhead Expands REDEMPLO Access for FCS in Germany
PASADENA, Calif., August 17, 2026 Arrowhead Pharmaceuticals, Inc. announced that people living with familial chylomicronaemia syndrome (FCS) in Germany...
Biomea Fusion Doses First Patient in Obesity OPAL Study
SAN CARLOS, Calif., August 13, 2026 Biomea Fusion, Inc. announced that the first participant has been dosed in a...
FlyteHealth Expands Medicare Care Through CMS Platform
NEW CANAAN, Conn., July 28, 2026 FlyteHealth has achieved General Availability within the Centers for Medicare & Medicaid Services...
Aqua Medical Treats First U.S. Patient in Diabetes Trial
PLEASANTON, Calif., July 28, 2026 Aqua Medical, Inc. has achieved a major clinical milestone with the successful treatment of...
Seegene Expands Precision Diagnostics for Women’s Health
SEOUL, South Korea, July 27, 2026 Seegene Inc., a global leader in molecular diagnostics, has introduced a comprehensive syndromic...
Advertisement
